Home › RXi Pharmaceuticals Corp (RXII) Upgraded to "Buy" at Zacks Investment Research
 

Keywords :   


RXi Pharmaceuticals Corp (RXII) Upgraded to "Buy" at Zacks Investment Research

2016-02-08 01:00:49| Biotech - Topix.net

The brokerage currently has a $0.25 price target on the biotechnology company's stock. Zacks Investment Research 's price objective would indicate a potential downside of 13.67% from the company's current price.

Tags: buy research investment corp

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05ABG announces leadership transition
16.05CeraVe Expands Sun Safety Day Initiative to Offer SPF Education Across the US this Summer
16.05Ex-Post Office IT boss blocked Vennells' number
16.05Covergirls New Eye Enhancer 3D Mascara Makes Eyes Pop
16.05ANEX to be Held in Taiwan Next Week
16.05Gov. Reynolds signs Iowa Meat Integrity Bill
16.05Gov. Reynolds signs Iowa Meat Integrity Bill
16.05Reality TV stars charged over investment plugs
More »